Место бевацизумаба в лечении больных раком яичников и раком шейки матки
- Авторы: Хохлова СВ1
-
Учреждения:
- ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава России
- Выпуск: Том 19, № 1 (2017)
- Страницы: 34-41
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/27118
- ID: 27118
Цитировать
Полный текст
Аннотация
Развитие цитостатической терапии как в лечении рака яичников, так и рака шейки матки зашло в тупик, поэтому в последние годы основной поиск исследований направляется на изучение биологии данных заболеваний. Ангиогенез является одним из основных факторов микроокружения опухоли, приводящим к росту и метастазированию заболеваний. В связи с этим начали появляться препараты, ингибирующие ангиогенез. Одним из первых препаратов, изученным в III фазе рандомизированных исследований, был бевацизумаб, который продемонстрировал достоверное увеличение как выживаемости без прогрессирования, так и продолжительности жизни в группе высокого риска больных при раке яичников и при рецидивах/диссеминированных формах рака шейки матки.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
С В Хохлова
ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава Россиид-р мед. наук, ст. науч. сотр. отд-ния химиотерапии ФГБУ «РОНЦ им.Н.Н.Блохина» 115478, Россия, Москва, Каширское ш., д. 23
Список литературы
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 63: 11-30.
- Bookman M. Trials with impact on clinical management: first line. Int J Gynecol Cancer 2009; 19 (Suppl. 2): S55-S62.
- American Cancer Society Facts and Figures 2016.
- Adegoke O, Kulasingam S, Virnig B. Cervical Cancer Trends in the United States: A 35-Year Population-Based Analysis. J Womens Health (Larchmt) 2012; 21 (10): 1031-7.
- Tewari K.S. Clinical implications for cediranib in advanced cervical cancer. Lancet Oncol 2015; 16 (15): 1447-8.
- Chien J, Kuang R, Landen C, Shridhar V. Platinum - sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol 2013; 3: 251.
- Galluzzi L, Senovilla L, Vitale I et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-83.
- Said N, Socha M.J, Olearczyk J.J et al. Motamed. Normalization of the ovarian cancer microenvironment by SPARC.Mol Cancer Res 2007; 5: 1015-30.
- Fukumura D, Jain R. Tumor microvasculature and microenvironment: targets for anti - angiogenesis and normalization. Microvasc Res 2007; 74: 72-84.
- Kassis J, Klominek J, Kohn E.C. Tumor microenvironment: what can effusions teach us? Diagn Cytopathol 2005; 33: 316-9.
- Leinster D.A, Kulbe H, Everitt G et al. The peritoneal tumour microenvironment of high - grade serous ovarian cancer. J Pathol 2012; 227: 136-45.
- Eskander R.N, Randall L.M. Bevacizumab in the treatment of ovarian cancer. Biologics 2011; 5: 1-5.
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
- Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 1999; 77: 527-43.
- Burger R.A, Sill M.W, Monk B.J et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25 (33): 5165-71.
- Cannistra S.A, Matulonis U.A, Penson R.T et al. Phase II study of bevacizumab in patients with platinum - resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25 (33): 5180-6.
- Garcia A, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low - dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26: 76-82.
- Tillmanns T.D et al. Phase II clinical trial of bevacizumab with albumin - bound paclitaxel in patients with recurrent, platinum - resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2013; 128: 221-28.
- Eskander R.N, Krishnansu S. Incorporation of anti - angiogenesis therapy in the management of advanced ovarian carcinoma - Mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 2014; 132 (2): 496-505.
- Huichung Tina Ling et al. A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer. ASCO 2014. Abst. 5564
- Sjoquist K.M et al. The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy - resistant ovarian cancer. ASCO 2014. Abst. TPS5627.
- Aghajanian C, Blank S.V, Goff B.A et al. OCEANS: a randomized, double - blind, placebo - controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum - sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-45.
- Pujade-Lauraine E.F.H, Weber B, Reuss A et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012; 30 [Suppl.; abstr LBA5002].
- Witteveen A.L.P, Fehm T, Poveda A et al. Final overall survival (OS) results from AURELIA, an open - label randomised phase IIItrial of chemotherapy (CT) with or without bevacizumab (BEV) for platinumresistant recurrent ovarian cancer (OC). Eur J Cancer 2013; 49 (Suppl. 3) LBA 5.
- Lauraine E, Hilpert F, Weber B et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 2012;30 (Suppl; abstr LBA5002).
- Burger R.A, Brady M.F, Bookman M.A et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-83.
- Burger R, Bookman M, Monk B et al. Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first - line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 120: S5.
- Perren T.J, Swart A.M, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96.
- Oza A.M, Swart A.M, Schröder W et al. ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer 2013; 49 (Suppl. 3).
- Wright J.D, Viviano D, Powell M.A et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006; 103 (2): 489-93.
- Monk B.J, Still M.W, Burger R.A et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009; 27 (7): 1069-74.
- Zighelboim I, Wright J.D, Feng Gaoc F et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013; 130 (1): 64-8.
- Tewari K.S, Sill M.W, Long H.J 3rd et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370 (8): 734-43.
- Penson R.T, Huang H.Q, Wenzel L.B et al. Bevacizumab for advanced cervical cancer: patient - reported outcomes of a randomized, phase 3 trial (NRG Oncology - Gynecologic Oncology Group protocol 240). Lancet Oncol 2015; 16 (3): 301-11.
- Bevacizumab [package insert]. Genetech, Inc, San Francisco, CA.
- Mourad J.J, des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19 (5): 927-34.
- Stone R.L, Sood A.K, Coleman R.L. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010; 11 (5): 465-75.
- Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J 2008; 29 (19): 2325-6.
- Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta - analysis. Lancet Oncol 2009; 10 (6): 559-68.
- Gordon C.R, Rojavin Y, Patel M et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009; 62 (6): 707-9.
- Scappaticci F.A, Fehrenbach L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91 (3): 173-80.
- Clark A.J, Butowski N.A, Chang S.M et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2011; 114 (6): 1609-16.